PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development ProgramCybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition of a phase 1 N,N-Dimethyltryptamine (“N,N-DMT”) study, the largest DMT study to date. The study provides key data relating to the company’s proprietary CYB004 substance with the potential to effectively treat anxiety disorders. “The phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary… The adaptive, randomized, double-blinded, placebo-controlled, single-ascending-dose study produced notable results. According to the study, inhaled CYB004 showed an estimated 2,000% improved bioavailability compared with orally administered DMT and a 41% improved bioavailability compared with inhaled DMT. In addition, Cybin’s CYB004 demonstrated an approximately 300% longer duration of effect when compared with IV DMT as well as a rapid onset of effects and low variability equivalent to IV DMT,” explains a recent article. “The most precious commodity in drug development is time and acquiring this robust phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months,” said Cybin CEO Doug Drysdale.
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) . The DMT study, which is the largest to date, is expected to accelerate the clinical development path of Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, CYB004, by approximately nine months. “With the closing of this transaction, we are well on our way to advancing CYB004 through phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule,” said Cybin CEO Doug Drysdale. “Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.”
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap ConferenceEntheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming trial, EBRX-101 is designed to be one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT to advance it as a therapy for addiction disorder.
BTV Investor Alert Video: Entheon Biomedical Corp. - Treating AddictionVancouver, British Columbia--(Newsfile Corp. - November 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) - Researching and developing DMT, one...
Entheon Biomedical Provides Corporate Update on Studies and Clinical TrialsVancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory BoardVancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Corp. Announces DTC EligibilityVancouver, British Columbia--(Newsfile Corp. - August 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics MarketVancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business...
BTV Examines the Rapidly Expanding Psychedelics MarketVancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business...
Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of KetamineVancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy GreenshawVancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Announces Medical Advisor, Dr. Dinesh BhayanaVancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit AwarenessVancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third WaveVancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit PartnershipVancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"), a...
Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.Vancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"...
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in USVancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem GroupVancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or...
Entheon Biomedical Corp. Provides Corporate UpdateLaunch of Psychedelics DNA Test KitPhase 1 clinical trial for DMT progressing as plannedPre-clinical In Vivo work scheduled to start...
Entheon Biomedical Lists on OTCQB Venture MarketVancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") ("Entheon" or...
